Key Highlights

  • Shares traded up USD 0.0911, or 17.59%, to USD 0.6089 in pre-market trading on November 4, 2026.
  • No company announcement dated November 2 to November 4, 2026 was identified.
  • Cash was USD 3,609,442 on June 30, 2026, versus USD 6,346,921 at December 31, 2025.
  • The second-quarter 2026 net loss was USD 1,208,534, and the filing raised substantial doubt about going concern.
  • A Phase 2a study of Ketamir-2 in chemotherapy-induced peripheral neuropathy advanced toward site initiation on September 17, 2026.

What Moved MIRA Pharmaceuticals Before the Open (up USD 0.0911, 17.59%)

MIRA Pharmaceuticals (NASDAQ:MIRA) was up USD 0.0911, or 17.59%, to USD 0.6089 in pre-market trading on November 4, 2026. That implies a Tuesday, November 3 close near USD 0.5178 (calculated from the screen figures).

No press release, regulatory filing or Earnings report from the company dated November 2 to November 4, 2026 was identified. Without a stated trigger, the likeliest drivers are momentum in low-priced biotech shares, a bounce after recent weakness and speculative positioning ahead of the open. These are possibilities, not confirmed causes.

The Most Recent Company Updates

The latest items on record are pipeline updates. According to a company press release dated October 22, 2026, MIRA reported that oral MIRA-55 reduced chronic inflammatory pain and swelling in a rat study, with effects described as comparable to a widely used anti-inflammatory at higher doses. The company said pain relief lasted 21 days and that it is working toward an investigational new drug filing in 2027.

On September 17, 2026, the company said its Phase 2a program for Ketamir-2 in chemotherapy-induced peripheral neuropathy had advanced toward site initiation after the FDA reviewed the protocol. The protocol had been submitted for institutional review board review at a leading cancer research institution.

A company press release dated June 17, 2026 described a randomized, double-blind, placebo-controlled crossover design testing 300 mg and 600 mg doses against placebo.

Business Background and Results

MIRA is a Miami-based clinical-stage pharmaceutical company developing oral drug candidates for neurologic, neuropsychiatric and metabolic conditions. Ketamir-2 is an oral NMDA receptor modulator that the company says the DEA confirmed as non-scheduled. The Phase 1 program enrolled 56 healthy volunteers, and the company reported no serious adverse events or dose-limiting toxicities.

Ketamir-2 is not approved for any use, and its safety and efficacy have not been established.

The second-quarter 2026 Form 10-Q showed operating expenses of USD 1,156,119, made up of USD 705,789 in Research and Development and USD 450,330 in general and administrative costs.

Balance Sheet and Risks

Cash fell to USD 3,609,442 on June 30, 2026 from USD 6,346,921 at December 31, 2025, a drop of about USD 2.7 million (calculated). Management said cash is not enough to fund operations for at least 12 months, and the filing stated that these factors raise substantial doubt about the company's ability to continue as a going concern. Shares outstanding were 42,022,087 as of August 10, 2026.

The company has an at-the-market agreement allowing aggregate sales of up to USD 75 million, and it did not use it in the first half of 2026. Any future use would add shares and could dilute holders. As a stock under USD 5, MIRA can swing sharply, trade with limited Liquidity and carry dilution risk.

What to Watch Next

Investors will look for a company statement explaining the move, along with the third-quarter 2026 Form 10-Q, which will update cash and the Going Concern language. Progress on site initiation for the Ketamir-2 Phase 2a study and any financing disclosure will also matter. Pre-market gains of this size can fade or reverse once regular trading opens.